Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

3.87
0.0000
Volume:- -
Turnover:- -
Market Cap:26.56M
PE:-1.08
High:3.87
Open:3.87
Low:3.87
Close:3.87
52wk High:23.43
52wk Low:2.90
Shares:6.86M
Float Shares:6.46M
Volume Ratio:1.39
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5690
EPS(LYR):-7.2500
ROE:-614.05%
ROA:-135.36%
PB:4.86
PE(LYR):-0.53

Loading ...

Plus Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $57 From $65

THOMSON REUTERS
·
Jun 08

Plus Therapeutics files $100M mixed securities shelf

TIPRANKS
·
Jun 02

BRIEF-Plus Therapeutics - May Offer And Sell Up To $100 Million Of Securities From Time To Time - SEC Filing

Reuters
·
Jun 02

Plus Therapeutics - May Offer and Sell up to $100 Mln of Securities From Time to Time - SEC Filing

THOMSON REUTERS
·
Jun 02

Plus Therapeutics - Equity Distribution Agreement Covers up to $17.35 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 02

Plus Therapeutics says CNSide cost-of-care analysis shows up to 40% reduction in leptomeningeal metastases healthcare costs

Reuters
·
May 26

Plus' Cnside Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients With Leptomeningeal Metastases

THOMSON REUTERS
·
May 26

Analysts’ Top Healthcare Picks: Upstream Bio, Inc. (UPB), Plus Therapeutics (PSTV)

TIPRANKS
·
May 19

Plus Therapeutics enters pact with Ephemeral for AI execution platform

TIPRANKS
·
May 19

Plus Therapeutics partners with Ephemeral Technologies on AI platform for CNS oncology

Reuters
·
May 19

Plus Therapeutics shareholders elect directors at annual meeting

Reuters
·
May 16

Plus Therapeutics Q1 net loss narrows

Reuters
·
May 16

BRIEF-Plus Therapeutics Q1 Net Income USD -6.946 Million

Reuters
·
May 16

Plus Therapeutics: Reaffirming Milestone Framework & 2026 Outlook

THOMSON REUTERS
·
May 16

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)

TIPRANKS
·
May 09

Plus Therapeutics highlights Phase 1 ReSPECT-LM REYOBIQ data in AANS plenary session

Reuters
·
May 08

Plus Therapeutics Announces Oral Presentation Highlighting Reyobiq™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

THOMSON REUTERS
·
May 08

Plus Therapeutics unit wins Medicare enrollment approval for CNSide diagnostic lab

Reuters
·
May 07

BRIEF-Plus Therapeutics Receives Medicare Enrollment Approval For Cnside Diagnostic

Reuters
·
May 07

Plus Therapeutics Inc - Payment Rate for Cpt Code 0640U Effective for Billing July 1, 2026

THOMSON REUTERS
·
May 07